Boyle Dana, the Chief Accounting Officer of Liquidia Corp, recently filed a report detailing significant stock transactions. This filing is important as it sheds light on how executives manage their equity compensation amid the pharmaceutical industry's ongoing challenges.
Background
Liquidia Corp, identified under the Central Index Key 0001819576, operates in the pharmaceutical preparations sector. The company is headquartered in Morrisville, North Carolina, and is listed under the ticker symbol LQDA. Recent filings include several Form 4 submissions, with the latest dated October 13, 2026.
What the Filing Says
The recent filing reveals that Dana Boyle acquired 3,178 shares of Liquidia Corp on October 9, 2026, and sold 5,892 shares on October 12, 2026, at a price of $28.48 per share. Following these transactions, Boyle holds a total of 165,609 shares.
Impact
This activity may impact investor sentiment, as executive transactions can often signal confidence or concern regarding a company's future performance. Such transactions are closely monitored by market participants, especially in the pharmaceutical sector, where regulatory and competitive pressures are significant.
What's Next
The filing does not say what happens next.
Details of Stock Transactions
In addition to the acquisition and sale of common stock, the filing indicates that Dana Boyle also received 3,178 shares in the form of Performance Stock Units (PSUs) on October 9, 2026. These PSUs convert into common stock on a one-for-one basis and are part of a larger grant of 50,861 PSUs that were awarded on January 11, 2025, with a vesting schedule that includes quarterly vesting over three years.
Ownership Breakdown
Following the transactions, Dana Boyle's total holdings include 165,609 shares of common stock, which encompasses both vested and unvested restricted stock units (RSUs). Specifically, Boyle holds 6,250 unvested RSUs from a grant of 50,000 RSUs made on January 25, 2023, as well as additional unvested RSUs from subsequent grants, totaling 86,612 unvested RSUs across various awards.
Tax Implications
The sale of 5,892 shares on October 12, 2026, was executed to cover tax obligations arising from the settlement of RSUs and PSUs granted on earlier dates. This strategic move highlights the financial planning involved in managing equity compensation.
Regulatory Compliance
It is noteworthy that the transactions were conducted under a Rule 10b5-1 plan adopted by Boyle on December 15, 2023. This plan allows for predetermined stock trades to be executed, providing an avenue for executives to manage their stock holdings while adhering to insider trading regulations.
Filing Context
The filing is part of a series of disclosures required by the SEC under the 1934 Act, aimed at promoting transparency regarding insider transactions. It reflects the ongoing regulatory framework that governs trading by corporate insiders, particularly in the pharmaceutical industry where market dynamics can be volatile.